Rescue therapy for serious infections in hospitalized patients;Tratamiento de rescate en las infecciones graves de los pacientes hospitalizados

Revista Espanola de Quimioterapia

Volumn 20, Issue 2, 2007, Pages 234-240

  Álvarez Lerma, Francisco ^a   Grau, S ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG SAFETY; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; MICROORGANISM; NOTE; PATHOGENESIS; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; CRITICAL CARE; CROSS INFECTION; DISEASE MANAGEMENT; DRUG RESISTANCE, MICROBIAL; HUMANS; SALVAGE THERAPY;

EID: 34548291518     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (57)

1. Alberti, C., Brun-Buisson, C., Burchardi, H. y cols. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28:108-121.
2. Mandell, L.A., Wunderink, R.G., Ansueto, A. y cols. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl. 2): S27-S72.
3. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
4. Stevens, D.L., Bisno, A.L., Chambers, H.F. y cols. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 1373-1406.
5. Jordá Marcos, R., Torres Martí, A., Ariza Cardenal, F.J., Álvarez Lerma, F., Barcenilla Gaite, F. y comisión de expertos de SEMICYUC, SEPAR y SEIMC. Recomendaciones para el tratamiento de la neumonía nosocomial grave. Enferm Infecc Microbiol Clin 2004; 22: 471-485.
6. Álvarez Lerma, F., Grau, S., Gracia Arnillas, M.P. Gram-positive cocci infections in intensive care: Guide to antibacterial selection. Drugs 2006; 66: 751-768.
7. Álvarez-Rocha, L., Alós, J.I., Blanquer, J. y cols. Guías para el manejo de la neumonía comunitaria del adulto que precisa ingreso en el hospital. Med Intensiva 2005; 29: 21-62.
8. Oleachea, P.M., Garnacho, J., Grau, S. y cols. Recomendaciones GEIPC-SEIMC y GTEI-SEMICYUC para el tratamiento antibiótico de infecciones por cocos grampositivos en el paciente crítico. Med Intensiva 2007; 31: 294-317.
9. Álvarez-Lerma, F. Modification of empiric treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22: 387-394.
10. Kollef, M.H., Sherman, G., Ward, S., Fraser, V.J. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
11. Iregui, M., Ward, S., Sherman, G., Fraser, V.J., Kollef, M.H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
12. Luna, C.M., Vujacich, P., Niederman, M.S. y cols. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
13. Ibrahim, E.H., Sherman, G., Ward, S., Fraser, V.J., Kollef, H.K. The influence of inadequate antimicrobial treatment of bloodstream infections on patient in the ICU setting. Chest 2000; 118: 146-155.
14. Leibovici, L., Shraga, I., Drucker, M. y cols. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 224: 379-386.
15. Zaragoza, R., Artero, A., Camarena, J.J. y cols. The influence of inadequate empirical antrimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003; 9: 412-418.
16. Grupo de Trabajo de Enfermedades Infecciosas (SEMICYUC). Estudio Nacional de Vigilancia de Infección Nosocomial en UCI. Informe anual. Grupo de Trabajo de Enfermedades Infecciosas (SEMICYUC) 2006.
17. Kollef, M.H. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001; 5: 189-195.
18. Kollef, M.H., Sherman, C. Ward, S., Fraser, V.J. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
19. Kang, C.I., Kim, S.H., Park, W.B. y cols. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: Risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49: 3980-3981.
20. Vallés, J., Rello, J., Ochagavia, A., Garnacho, J., Alcalá, M.A. Community-acquired bloodstream infection in critically ill adult patients: Impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123: 1615-1624.
21. Ibrahim, E.H., Ward, S., Sherman, G. y cols. Experience with a clinical guidelines for the treatment of ventilador-associated pneumonia. Crit Care Med 2001; 29: 1109-1115.
22. Soo Hoo, G.W., Wen, Y.E., Nguyen, T.V., Goetz, M.B. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128: 2778-2787.
23. Álvarez Lerma, F., Olaechea Astigarraga, P. Impact of hospital-acquired pneumonia (HAP) guidelines on outcome. Respiratory infections. Clin Pulm Infect 2007; 14: 7-12.
24. Trouillet, J.L., Chastre, J., Vuagnat, A. y cols. Ventilator- associated pneumonia caused by potentially drug-resistant bacteria. Am J Resp Crit Care Med 1998; 157: 531-539.
25. Álvarez Lerma, F., Álvarez, B., Luque, P. y cols. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: A prospective observational study. Crit Care 2006; 10: R78.
26. Domínguez, A.A., Arango, M.V., Torres, A. Treatment failure in patients with ventilator-associated pneumonia. Semin Respir Crit Care Med 2006; 27: 104-114.
27. Marshall, J.C., Cook, D.J., Christou, N.V. y cols. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23: 1638-1652.
28. Menéndez, R., Torres, A. Predicting poor outcome of pneumoniae. Arch Bronconeumol 2005; 41: 574-577.
29. Vidaur, L., Gualis, B., Rodríguez, A. y cols. Clinical resolution in patients with suspicion of ventilator-associated pneumoniae: A cohort study comparing patients with and without acute respiratory distress syndrome. Crit Care Med 2005; 33: 1248-1253.
30. Stolz, D., Christ-Crain, M., Gencay, M.M. y cols. Diagnostic value of signs, symptoms and laboratory values in lower respiratory tract infections. Swiss Med Wkly 2006; 136: 434-440.
31. Christ-Crain, M., Stols, D., Bingisser, R. y cols. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Resp Crit Care Med 2006; 174: 84-93.
32. Fink, M.P., Snydman, D.R., Niederman, M.S. y cols. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with impipenem- cilastatin. Antimicrob Agents Chemother 1994; 38: 547-557.
33. Chamot, E., El Amari, E.B., Rohner, P., Van Delden, C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47: 2756-2764.
34. El Amari, E.B., Chamot, E., Auckenthaler, R., Pechere, J.C., Van Delden, C. Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis 2001; 33: 1859-1864.
35. Harris, A.D., Perencevich, E., Roghmann, M.C. y cols. Risks factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002; 46: 854-858.
36. Ozkurt, Z., Ertek, M., Erol, S., Altoparlak, U., Akcay, M.N. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31: 870-873.
37. Graffunder, E.M., Venecia, R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
38. Webber, S.G., Gold, H.S., Hopper, D.C., Karchmer, A.W., Carmeli, Y. Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis 2003; 9: 1415-1422.
39. Prescott, W.A., Kusmierski, K.A. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007; 27: 137-142.
40. Papadopoulos, N.G., Konstantinou, D.N. Antimicrobial strategies: An option to treat allergy? Biomed Pharmacother 2007; 61: 21-218.
41. Arundel, C., Lewis, J.H. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007; 23: 244-254.
42. Grau, S., Berenguer, N., Luque, S., Mateu de Antonio, J. Desabastecimiento de cefepime y aztreonam: Nos quedamos sin municiones. Enferm Infecc Med Clin 2007; 25: 360-361.
43. Dellit, T.H., Owens, R.C., McGowan, J.E. y cols. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44: 159-177.
44. Hoban, J., Bouchillon, S.K., Johnson, B.M., Jonson, J.L. Dowzicky, M.J. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST program, 2004). Diag Microb Infect Dis 2005; 52: 215-227.
45. Meagher, A.K., Ambrose, P.G., Grasela, T.H., Ellis-Grosse, E.J. The pharmacokinetic and pharmacodynamic profile of tigecicline. Clin Infect Dis 2005; 41: S333-340.
46. Stein, G.E., Craig, W.A. Tigecycline: A critical analysis. Clin Infect Dis 2006; 43: 518-524.
47. Kasiakou, S.K., Michalopoulos, A., Soteriades, E.S. y cols. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients witout cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-3146.
48. Tascini, C., Gemignani, G., Palumbo, F. y cols. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006; 18: 6486-651.
49. Falagas, M.E., Kasiakou, S.K. Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
50. Rahal, J.J., Urban, C., Horn, D. y cols. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233-1237.
51. Martínez, J.A., Aguilar, J., Almela, M. y cols. Prior use of carbapenems may be a significant risk factor for extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother 2006; 58: 1092-1095.
52. Quintela Fandino, M., Coto López, A., Fernández Miranda, C. Acidosis metabólica grave en un paciente tratado con trimetoprim-sulfametoxazol. Factores fisiopatológicos. An Med Inter 2003; 20: 443-444.
53. Hoffken, G., Niederman, M.S. Nosocomial pneumonia: The importance of a de-escalation strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183-2196.
54. Kasiakou, S.K., Lawrence, K.R., Choulis, N., Falagas, M.E. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: A systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs 2005; 65: 2499-2511.
55. Grupper, M., Sprecher, H., Mashiach, T., Finkelstein, R. Attributable mortality of nosocomial Acinetobacter bacteriemia. Infect Control Hosp Epidemiol 2007; 28: 293-288.
56. Gómez, G., García-Vázquez, E., Baños, R. y cols. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007; 26: 239-245.
57. Mallick, R., Sun, S., Schell, S.R. Predictors of efficacy and health resource utilization in treatment of complicated intra-abdominal infections: Evidence for pooled clinical studies comparing tigecycline with imipenem-cilastatin. Surg Infect 2007; 8: 159-172.